Alphagan

   
Google
 
Web NewDrugInformation.com

Alphagan


Drug - Alphagan
The trade name of the product as shown on the labeling.

Dosage - SOLUTION/DROPS; OPHTHALMIC
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Brimonidine Tartrate
Multiple ingredients are in alphabetical order.

Strength - 0.2%
The potency of the active ingredient(s), Brimonidine Tartrate. May repeat for multiple part products.

Applicant - ALLERGAN
The firm name holding legal responsibility for Alphagan. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 020613
The FDA assigned number to Alphagan. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Alphagan. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Sep 6, 1996
The date Alphagan was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - No
The pioneer or innovator of Alphagan. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - DISCN
The group or category of approved drugs Alphagan is in. Format is RX, OTC, DISCN.

Applicant Full Name - Allergan Inc
The full name of the firm holding legal responsibility for the new application of Alphagan.

Alphagan